These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25461960)

  • 1. Effect of Intravenous Versus Subcutaneous Phytonadione on Length of Stay for Patients in Need of Urgent Warfarin Reversal.
    Mottice BL; Soric MM; Legros E
    Am J Ther; 2016; 23(2):e345-9. PubMed ID: 25461960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study.
    Lubetsky A; Yonath H; Olchovsky D; Loebstein R; Halkin H; Ezra D
    Arch Intern Med; 2003 Nov; 163(20):2469-73. PubMed ID: 14609783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione.
    Raj G; Kumar R; McKinney WP
    Arch Intern Med; 1999 Dec 13-27; 159(22):2721-4. PubMed ID: 10597763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio.
    Byrd DC; Stephens MA; Hamann GL; Dorko C
    Am J Health Syst Pharm; 1999 Nov; 56(22):2312-5. PubMed ID: 10582823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
    Tsu LV; Dienes JE; Dager WE
    Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
    Shields RC; McBane RD; Kuiper JD; Li H; Heit JA
    Mayo Clin Proc; 2001 Mar; 76(3):260-6. PubMed ID: 11243272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation.
    Patel RJ; Witt DM; Saseen JJ; Tillman DJ; Wilkinson DS
    Pharmacotherapy; 2000 Oct; 20(10):1159-66. PubMed ID: 11034038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation.
    Whitling AM; Bussey HI; Lyons RM
    Arch Intern Med; 1998 Oct; 158(19):2136-40. PubMed ID: 9801181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous phytonadione administered orally in reducing warfarin-related coagulopathy.
    Rice JH; Akpunonu P; Davis GA; Dugan A; Litteral J; Webb AN; Wiegand A; Bailey A; Baum RA
    Clin Toxicol (Phila); 2022 Apr; 60(4):530-532. PubMed ID: 34751053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of various phytonadione (vitamin K1) administration routes in achieving warfarin reversal.
    Laible B
    S D Med; 2007 Apr; 60(4):158-9. PubMed ID: 17555152
    [No Abstract]   [Full Text] [Related]  

  • 11. Time to Peak International Normalized Ratio Rise in Acute and Acute-on-Chronic Warfarin Overdoses.
    Minhaj FS; Leonard JB; Seung H; Klein-Schwartz W
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):474-479. PubMed ID: 34516454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation.
    Nee R; Doppenschmidt D; Donovan DJ; Andrews TC
    Am J Cardiol; 1999 Jan; 83(2):286-8, A6-7. PubMed ID: 10073841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin.
    Fan J; Armitstead JA; Adams AG; Davis GA
    Pharmacotherapy; 2003 Oct; 23(10):1245-50. PubMed ID: 14594342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.
    Dezee KJ; Shimeall WT; Douglas KM; Shumway NM; O'malley PG
    Arch Intern Med; 2006 Feb; 166(4):391-7. PubMed ID: 16505257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of warfarin-induced hypoprothrombinemia with use of low-dose subcutaneous vitamin K1.
    Fetrow CW; Overlock T; Leff L
    J Clin Pharmacol; 1997 Aug; 37(8):751-7. PubMed ID: 9378848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative warfarin reversal for early hip fracture surgery.
    Moores TS; Beaven A; Cattell AE; Baker C; Roberts PJ
    J Orthop Surg (Hong Kong); 2015 Apr; 23(1):33-6. PubMed ID: 25920640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
    Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
    Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation management in individuals with hip fracture.
    Gleason LJ; Mendelson DA; Kates SL; Friedman SM
    J Am Geriatr Soc; 2014 Jan; 62(1):159-64. PubMed ID: 24383759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of different warfarin reversal protocols on surgical delay and complication rate in hip fracture patients.
    Leonidou A; Rallan R; Cox N; Pagkalos J; Luscombe J
    J Orthop Surg (Hong Kong); 2013 Aug; 21(2):142-5. PubMed ID: 24014771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral vitamin K1: an option to reduce warfarin's activity.
    Harrell CC; Kline SS
    Ann Pharmacother; 1995 Dec; 29(12):1228-32. PubMed ID: 8672826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.